Company Overview and News

 
A place to stay in Spain: Bubble, cube, castle, monastery or tree-house?

2018-10-13 thinkspain
WHEN is a hotel not a hotel? When it's a bubble, a cave or a castle, naturally.
500413 THOMASCOOK

 
Thomas Cook (India) Limited - Trading Window

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

1
CANADA STOCKS-Futures edge higher as global stocks rebound

2018-10-12 reuters
Oct 12 (Friday) - Stock futures for Canada’s main stock index edged higher on Friday, tracking global equity markets, which bounced back after a sharp selloff this week.
ENBBF ENB 500413 APH LHSIF EBBNF ENB APHQF THOMASCOOK

 
Air Transat-Thomas Cook partnership: Canadian airline says deal could expand

2018-10-12 financialexpress
Canada’s Air Transat could expand a partnership deal with the airline arm of British tourism group Thomas Cook to include codesharing and interlining, the boss of the Canadian carrier said. Codesharing is a way of airlines selling each other’s tickets and then sharing passengers on a flight offered by the partner airline, while interlining involves partner airlines operating one connection on a two-leg journey.
500413 THOMASCOOK

 
Canada's Air Transat says airline deal with Thomas Cook could expand

2018-10-12 reuters
LONDON (Reuters) - Canada’s Air Transat (TRZ.TO) could expand a partnership deal with the airline arm of British tourism group Thomas Cook (TCG.L) to include codesharing and interlining, the boss of the Canadian carrier said.
500413 THOMASCOOK

 
Hundreds of passengers on German cruise ship catch stomach bug

2018-10-10 thinkspain
A STOMACH bug 'doing the rounds' led to 300 passengers on a German cruise ship being treated by doctors flown in from the central European country this week.
500413 THOMASCOOK

 
Ryanair 'not liable' for cancellation compensation, says Barcelona court

2018-10-08 thinkspain
A BARCELONA court has turned down a compensation claim against Ryanair by a couple whose flight to Portugal was cancelled as a result of the strikes.
500413 THOMASCOOK

 
Altamira, Cantabria: 150 years since world's first cave art discovery

2018-10-06 thinkspain
A DOG, a weaver, an eight-year-old girl and a landowner with a spade formed the cast.
500413 THOMASCOOK

 
Brits report 'vomit on seat' on Ryanair Alicante flight

2018-10-05 thinkspain
A BRITISH couple on a Ryanair flight from Alicante to claimed their seat was 'covered in dried vomit' and that the cabin crew 'refused to clean it'.
500413 THOMASCOOK

 
Company news: Thomas Cook India

2018-10-05 thehindubusinessline
The board of Thomas Cook India has approved acquisition of a 24 per cent strategic stake in TravelJunkie Solutions Private Limited, a Mumbai-based travel tech start-up, via its wholly-owned subsidiary TC Tours. TravelJunkie Solutions-developed Ithaka - a chat-based mobile application serving FIT (Free Individual Traveller) customers by recommending authentic local experiences for different destinations and helping plan their trip and book activities, hotels and flights.
500413 THOMASCOOK

 
Thomas Cook (India) Limited - ESOP/ESOS/ESPS

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

 
Thomas Cook (India) Limited - Updates

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

 
Thomas Cook (India) Limited - Trading Window

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

 
Thomas Cook (India) Limited - Credit Rating

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500413 THOMASCOOK

 
Market report: 

2018-10-01 telegraph.co.uk
London-focused housebuilder Berkeley flirted with a one-year low on fears that Government plans to deter foreign property buyers with a new tax will slow the capital’s stuttering housing market.
500413 THOMASCOOK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...